Oncology

Multiple Myeloma

Advertisement

Conference Reporter in Multiple Myeloma to Cover Key Topics Being Presented at the ASCO20 Virtual Scientific Program and the Virtual Edition of the 25th EHA Annual Congress

conference reporter by Paul G. Richardson, MD; Robert Z. Orlowski, MD, PhD; S. Vincent Rajkumar, MD

Overview

Conference Reporter delivers health care providers with insights from key thought leaders on exciting news presented at major medical conferences, in a concise and timely format. This issue of Conference Reporter will feature coverage of selected topics in Multiple Myeloma presented at this year’s ASCO and EHA annual meetings.

“Whether you are able to attend the virtual sessions or not, Conference Reporter in Multiple Myeloma will enhance your on-demand conference experience.”

Tom Iarocci, MD

The oncologists who were surveyed selected the following expert commentators and topics from the upcoming conferences.

Community-Selected Expert Commentators:

Robert Z. Orlowski, MD, PhD 

Director of Myeloma Section Department of Lymphoma/Myeloma Florence Maude Thomas Cancer Research Professor Department of Experimental Therapeutics Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, TX

S. Vincent Rajkumar, MD 

Edward W. and Betty Knight Scripps Professor of Medicine Mayo Clinic Rochester, MN

Paul G. Richardson, MD 

Clinical Program Leader and Director of Clinical Research Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute RJ Corman Professor of Medicine Harvard Medical School Boston, MA

Community-Selected Topics:

  • Multiple Myeloma Session Roundup: Measurable Residual Disease Assessment and Implications
  • Treatment of Patients With Relapsed/High-Risk Multiple Myeloma
  •  Clinical Considerations in Initial Treatment of Newly Diagnosed Patients With Multiple Myeloma
  •  Novel Agents in the Approach to Patients With High-Risk Multiple Myeloma
  •  Refractory Multiple Myeloma: Tailoring Treatment to Patient Characteristics
  •  CD38 and Its Expanding Role as an Immunomodulator and Druggable Target

This information is brought to you by Engage Health Media and is not sponsored by, nor a part of, the American Society of Clinical Oncology or the European Hematology Association.

Paul G. Richardson, MD

Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, MA

Robert Z. Orlowski, MD, PhD

Florence Maude Thomas Cancer Research Professor
Vice Chair, Myeloma Translational Research
Deputy Chair, Department of Lymphoma/Myeloma
Professor, Department of Experimental Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

S. Vincent Rajkumar, MD

Edward W. and Betty Knight Scripps Professor of Medicine
Mayo Clinic
Rochester, MN

Advertisement